Morgan Stanley displays unwavering optimism about the sector MedTech in 2024, despite the challenges faced by certain companies. The agency upgraded its ratings for Intuitive Surgical And Stryker, demonstrating its confidence in their growth potential. At the same time, it lowered its evaluations to Neuro And Glaukos, illustrating a nuanced analysis of market dynamics.
Morgan Stanley takes a positive view of the sector MedTech for the year 2024, despite the difficulties encountered. The financial institution has chosen to raise the outlook for Intuitive Surgical And Stryker, recognizing the strength of their position in the market. At the same time, the scores awarded to Neuro And Glaukos were lowered, reflecting specific concerns within their respective businesses. This approach underlines the resilience of the sector in the face of current challenges and confidence in its future development.
Morgan Stanley maintains a positive view on the MedTech sector
Morgan Stanley recently updated its outlook on the sector MedTech, indicating that they remain attractive despite the challenges encountered. This optimistic position is based on solid fundamentals and the belief that concerns, particularly those around GLP-1s, are now integrated into stock prices. In 2024, although unforeseen obstacles have arisen, particularly for companies like DexCom And Edwards Life Sciences, the sector still shows promising sales volumes.
Upgrades for Intuitive Surgical and Stryker, drops for Nevro and Glaukos
Note revisions by Morgan Stanley focused on certain key companies in the sector. Intuitive Surgical And Stryker received upward revisions from a rating ofequality has overweighting. This improvement in the status of Intuitive Surgical is mainly attributed to the high demand for the system Da Vinci Dv5 which seems to exceed market expectations. For Stryker, although orthopedic procedure volumes are uncertain, a large order backlog could boost growth, bringing a bright future for the entire industry.
Perspectives for the future of the MedTech sector
Despite the concerns that still linger, analysts anticipate that the dynamic will remain favorable towards 2025. Morgan Stanley highlights the strength of blowjobs and volumes in the sector MedTech, suggesting that this strength protects the sector against possible delays related to FDA regulatory requirements. According to experts, even if occasional surprises are expected, the general trend seems promising. Investor choices must be made carefully, especially for stocks like those of Glaukos And Neuro, which suffered outlook cuts this quarter.
